Investors in Exelixis Inc (Symbol: EXEL) saw new options become available this week, for the November 21st expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Another notable valuation metric for EXEL is its P/B ratio of 4.54. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.

so it seems like value investors will conclude that EXEL is the superior option right now. This article originally published on Zacks Investment Research (zacks.com).

Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's strong performance.

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other ... should clinical studies be successful, offer an “option-like structure,” even ...

Explore Exelixis stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for EXEL. Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported ...

EXEL has seen stronger estimate revision activity and sports more attractive valuation metrics than TECH, so it seems like value investors will conclude that EXEL is the superior option right now.